Update is interesting30 Jan 2020 14:37
Directors are very pleased with the considerable progress that has been achieved on limited resources. Work on the core CDX antibody project with the Company's major pharmaceutical partner continues to progress with successful results achieved in further laboratory tests and with discussions ongoing as to its future development and funding. The separate development of a treatment for AML using HEMO-CAR-T has shown encouraging results to date and additional projects using the Company's ApbHC mice are under development.
The Directors are greatly encouraged by the overall progress made both with the CDX antibody project and by the number and quality of the new developments arising from this original core work.